Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,028 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N, Tsurumi H, Goto H, Shimomura YI, Kasahara S, Hara T, Yasuda I, Shimizu M, Murakami N, Yoshikawa T, Fukuno K, Takahashi T, Kito Y, Takami T, Moriwaki H. Goto N, et al. Among authors: goto h. Ann Hematol. 2012 May;91(5):705-714. doi: 10.1007/s00277-011-1363-4. Epub 2011 Dec 21. Ann Hematol. 2012. PMID: 22183251
Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Goto N, Okuno M, Takami T, Seishima M, Moriwaki H. Goto H, et al. Among authors: goto n. J Cancer Res Clin Oncol. 2005 Feb;131(2):73-9. doi: 10.1007/s00432-004-0600-9. Epub 2004 Oct 21. J Cancer Res Clin Oncol. 2005. PMID: 15503137
Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome.
Kojima Y, Tsurumi H, Goto N, Shimizu M, Kasahara S, Yamada T, Kanemura N, Hara T, Sawada M, Saio M, Yamada T, Takahashi T, Tomita E, Takami T, Moriwaki H. Kojima Y, et al. Among authors: goto n. Eur J Haematol. 2006 Jun;76(6):465-72. doi: 10.1111/j.1600-0609.2006.00631.x. Epub 2006 Feb 23. Eur J Haematol. 2006. PMID: 16494623 Free article.
Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U).
Kitagawa J, Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, Kasahara S, Yamada T, Sawada M, Takahashi T, Shimizu M, Takami T, Moriwaki H. Kitagawa J, et al. Among authors: goto n. J Cancer Res Clin Oncol. 2009 Jan;135(1):53-9. doi: 10.1007/s00432-008-0440-0. Epub 2008 Jul 1. J Cancer Res Clin Oncol. 2009. PMID: 18592269
Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP.
Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, Kasahara S, Yamada T, Sawada M, Goto H, Fukuno K, Kitagawa J, Yasuda I, Katsumura N, Takemura M, Takahashi T, Takami T, Moriwaki H. Hara T, et al. Among authors: goto n, goto h. J Cancer Res Clin Oncol. 2009 Oct;135(10):1421-8. doi: 10.1007/s00432-009-0586-4. Epub 2009 Apr 21. J Cancer Res Clin Oncol. 2009. PMID: 19381687
Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma.
Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, Kasahara S, Goto H, Fukuno K, Yamada T, Sawada M, Yasuda I, Katsumura N, Takahashi T, Takami T, Moriwaki H. Hara T, et al. Among authors: goto n, goto h. J Cancer Res Clin Oncol. 2010 Jan;136(1):65-70. doi: 10.1007/s00432-009-0637-x. J Cancer Res Clin Oncol. 2010. PMID: 19590893 Clinical Trial.
1,028 results